Performance of a fast-track pathway for giant cell arteritis in Waikato, Aotearoa New Zealand.
Philippa van Dantzig, Douglas White, Jason Kurz...
https://pubmed.ncbi.nlm.nih.gov/38513202/Actively Recruiting
Led by Groupe Hospitalier de la Rochelle Ré Aunis · Updated on 2025-06-20
100
Participants Needed
1
Research Sites
12 weeks
Total Duration
Giant Cell Arteritis GCA is an inflammation of artery walls mainly affecting people over 50 years old. The diagnosis can be difficult due to non-specific symptoms like headaches, jaw pain, and scalp tenderness, but it is important to diagnose quickly to avoid serious complications such as vision loss or stroke. Advances in ultrasound technology have improved early diagnosis by identifying a characteristic halo sign on temporal arteries, potentially reducing the need for biopsies. This research evaluates a fast-track diagnostic pathway designed to speed up the diagnosis of GCA. Patients suspected of having GCA undergo ultrasound exams of temporal and axillary arteries. If inflammation is seen on both sides, biopsy may be avoided. If ultrasound is negative or inconclusive, biopsy is performed. This approach aims to reduce diagnosis time from about 10 days to just one day and to minimize hospital stays and biopsies. Participants suspected of GCA will be assessed through clinical signs, ultrasound imaging, and if needed, biopsy. Researchers will measure the time from initial suspicion to ultrasound results and corticosteroid treatment start. They will also track cases with alternative diagnoses and compare ultrasound and biopsy findings. The study continues until March 2027 and seeks to improve early diagnosis and care for people with this condition.
CONDITIONS
Performance of a Fast-track Pathway for Giant Cell Arteritis Diagnosis
C
Caroline Allix-Béguec, Ph.D.
C
Cécile Duchiron, Ph.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Groupe Hospitalier de la Rochelle Ré Aunis
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 7 days
Participants suspected of Giant Cell Arteritis undergo ultrasound and may have biopsies to confirm diagnosis.
1 to 2 visits depending on ultrasound and biopsy results
Duration - Up to 1 month
Participants are followed up to assess final diagnosis and treatment outcomes.
1 follow-up visit
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Philippa van Dantzig, Douglas White, Jason Kurz...
https://pubmed.ncbi.nlm.nih.gov/38513202/Guillaume Denis, Olivier Espitia, Caroline Allix-Béguec...
https://pubmed.ncbi.nlm.nih.gov/38710093/Groupe Hospitalier de la Rochelle Ré Aunis
Lead Sponsor